Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT05961007
Other study ID # CIBI302B201
Secondary ID
Status Suspended
Phase Phase 1/Phase 2
First received
Last updated
Start date November 18, 2021
Est. completion date April 30, 2024

Study information

Verified date July 2023
Source Innovent Biologics (Suzhou) Co. Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the efficacy and safety of intravitreal IBI302 in the treatment of subjects with neovascular age-related macular degeneration (only in Phase I) or diabetic macular edema.


Recruitment information / eligibility

Status Suspended
Enrollment 234
Est. completion date April 30, 2024
Est. primary completion date October 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria 1. Willing and able to sign informed consent form and comply with visit and study procedures per protocol; 2. Male or female patiensubjects = 18 yrs. of age; 3. For AMD subjects, active subfoveal or parafoveal CNV secondary to neovascular AMD; the vision decreased by nAMD; 4. For DME subjects, Type 1 or type 2 diabetes mellitus, decrease in vision determined to be primarily the result of DME in the study eye; the CST measurement of = 280 µm in the study eye; 5. BCVA ETDRS letter score of 24-73 in the study eye; Exclusion criteria 1. Concomitant diseases that may cause subjects fail to respond to the treatment or confuse the interpretation of the study results; 2. Presence of uncontrolled glaucoma in the study eye ; 3. Presence of active intraocular or periocular inflammation or infection; 4. Prior any treatment of following in the study eye: 1. Anti-VEGF therapy or anti-complement therapy; 2. Laser photocoagulation; 3. History of vitreoretinal surgery; 4. Glucocorticoid treatment(intravitreal or peribulbar) ; 5. BCVA score <19 letters in the fellow eye; 6. Anti-VEGF therapy in the fellow eye within 30 days of day 0; 7. Presence of any systemic disease: including but not limited to active infections (such as active viral hepatitis); unstable angina; cerebrovascular accident or transient cerebral ischemia (within 6 months prior to screening); myocardial infarction (within 6 months prior to screening; serious arrhythmia requiring medical treatment; liver, kidney or metabolic diseases; uncontrolled clinical disease(such as diabetes mellitus, hypertension) or malignant tumor; 8. History of severe hypersensitivity/allergy to active ingredients or any excipients of the study drug, or fluorescein and povidone iodine; 9. Pregnant or lactating women or women preparing to become pregnant or breastfeeding during the study period; 10. Participated in any clinical study of any other drug within 90 days of day 0, or attempted to participate in other drug trials during the study; 11. Other conditions unsuitable for enrollment judged by investigatiors.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Intravitreal injection of IBI302(dose 1)
IBI302(dose 1) intravitreal injection given as protocol
Intravitreal injection of IBI302(dose 2)
IBI302(dose 2) intravitreal injection given as protocol
Intravitreal injection of IBI302(dose 3)
IBI302(dose 3) intravitreal injection given as protocol
Drug:
Intravitreal injection of Aflibercept
Aflibercept intravitreal injection given as protocol

Locations

Country Name City State
China Peking University People's Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Innovent Biologics (Suzhou) Co. Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence and severity of ocular and non-ocular adverse events. To evaluate the number of subjects with ocular and non-ocular adverse events, treatment emergent adverse event, adverse event of special interest, serious adverse events; number of subjects with clinical significant abnormal laboratory values, electrocardiograms (pre and post infusions), abnormal vital signs, ophthalmic and physical examinations. Up to week 20
Primary DLT in each group 7 days
Secondary Change of BCVA from baseline by visit Best corrected visual acuity (BCVA) was measured on early treatment diabetic retinopathy study(ETDRS) chart at a starting distance of 4 meters. The BCVAletter score ranges from 0 to 100(best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. through study completion,an average of 20 weeks
Secondary Change of CST from baseline by visit Central subfield thickness(CST) was defined as the distance between the internal limiting member and the Bruch's member using OCT, as assessed by the central reading. through study completion,an average of 20 weeks
Secondary Area under the concentration time curve (AUC) and Maximum plasma concentration (Cmax) through study completion,an average of 20 weeks
Secondary The ADA and neutralizing antibody Blood samples were obtained for measurement of anti-drug antibodies (ADAs) to IBI302 by a validated enzyme-linked immunosorbent assay (ELISA). through study completion,an average of 20 weeks
See also
  Status Clinical Trial Phase
Completed NCT03953807 - A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never Treated Phase 4
Completed NCT03622580 - A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE) Phase 3
Recruiting NCT06262737 - Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
Terminated NCT04611152 - A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) Phase 3
Terminated NCT04603937 - A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) Phase 3
Active, not recruiting NCT04108156 - This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab Phase 3
Completed NCT02867735 - A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema Phase 1
Withdrawn NCT03629210 - Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular Edema Phase 2
Withdrawn NCT02842541 - Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema Phase 1
Completed NCT02221453 - Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide Phase 2
Completed NCT02556723 - Intravitreal Injections of Ziv-aflibercept for Macular Diseases N/A
Completed NCT02979665 - Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema
Completed NCT02000102 - Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab N/A
Completed NCT02088229 - Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema N/A
Terminated NCT00779142 - Utility of Intravitreal Methotrexate in Diabetic Macular Edema Resistant to Conventional Therapies N/A
Completed NCT01171976 - Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus Phase 3
Completed NCT00989989 - Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema Phase 3
Completed NCT01259609 - Changes in Ciliary Body Thickness in Patients With Diabetic Macular Edema After Vitrectomy N/A
Terminated NCT00768040 - Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema Phase 2
Completed NCT00683176 - Effect of Choline Fenofibrate (SLV348) on Macular Edema Phase 2